MX2010001664A - Nuevos compuestos. - Google Patents

Nuevos compuestos.

Info

Publication number
MX2010001664A
MX2010001664A MX2010001664A MX2010001664A MX2010001664A MX 2010001664 A MX2010001664 A MX 2010001664A MX 2010001664 A MX2010001664 A MX 2010001664A MX 2010001664 A MX2010001664 A MX 2010001664A MX 2010001664 A MX2010001664 A MX 2010001664A
Authority
MX
Mexico
Prior art keywords
new compounds
production
compounds
salts
diastereomers
Prior art date
Application number
MX2010001664A
Other languages
English (en)
Inventor
Henri Doods
Norbert Hauel
Iris Kauffmann-Hefner
Ingo Konetzki
Annette Schuler-Metz
Rainer Walter
Angelo Ceci
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2007/058408 external-priority patent/WO2008022945A1/de
Priority claimed from PCT/EP2008/052157 external-priority patent/WO2009021758A1/de
Priority claimed from EP08102043A external-priority patent/EP2025673A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2010001664A publication Critical patent/MX2010001664A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Objeto de la presente invención son compuestos de la fórmula general (I) (ver fórmula I) en la que A, 'B, D, Y, R1, R2, R3, R4 y R5 se definen como se mencionaron en la descripción, sus enantiómeros, sus diastereómeros, sus mezclas y sus sales, en especial sus sales fisiológicamente tolerables con ácidos o bases orgánicos o inorgánicos, que presentan valiosas propiedades, su preparación, los medicamentos que contienen los compuestos farmacológicamente eficaces, su preparación y su uso.
MX2010001664A 2007-08-14 2008-08-12 Nuevos compuestos. MX2010001664A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2007/058408 WO2008022945A1 (de) 2006-08-19 2007-08-14 Arylsulfonamide mit analgetischer wirkung
PCT/EP2008/052157 WO2009021758A1 (de) 2007-08-14 2008-02-21 Arylsulfonamide mit analgetischer wirkung
EP08102043A EP2025673A1 (de) 2007-08-14 2008-02-26 Arylsulfonamide mit analgetischer Wirkung
PCT/EP2008/060562 WO2009021944A1 (de) 2007-08-14 2008-08-12 Neue verbindungen

Publications (1)

Publication Number Publication Date
MX2010001664A true MX2010001664A (es) 2010-03-10

Family

ID=40589564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001664A MX2010001664A (es) 2007-08-14 2008-08-12 Nuevos compuestos.

Country Status (21)

Country Link
US (1) US8394805B2 (es)
EP (1) EP2188269B1 (es)
JP (1) JP5250627B2 (es)
KR (1) KR20100055469A (es)
CN (1) CN101821245B (es)
AR (1) AR068341A1 (es)
AU (2) AU2008288431A1 (es)
BR (1) BRPI0815181A2 (es)
CA (1) CA2696261A1 (es)
CO (1) CO6331335A2 (es)
EA (1) EA201000296A1 (es)
EC (1) ECSP109978A (es)
MA (1) MA31613B1 (es)
MX (1) MX2010001664A (es)
NZ (1) NZ583815A (es)
PE (1) PE20090593A1 (es)
TN (1) TN2010000072A1 (es)
TW (1) TW200911744A (es)
UY (1) UY31287A1 (es)
WO (1) WO2009021944A1 (es)
ZA (1) ZA201008350B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006039003A1 (de) * 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
US8394805B2 (en) 2007-08-14 2013-03-12 Boehringer Ingelheim International Gmbh Compounds
EP2025675A1 (de) 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
US20110046106A1 (en) * 2008-02-06 2011-02-24 Boehringer Ingelheim International Gmbh Aryl sulfonamides as effective analgesics
BRPI0914556A2 (pt) * 2008-08-12 2015-08-04 Boehringer Ingelheim Int Processo para a preparação de compostos de piperazina substituídos por cicloalquila
US8207335B2 (en) * 2009-02-13 2012-06-26 Boehringer Ingelheim International Gmbh Process for making certain compounds having B1 antagonistic activity
WO2012017027A1 (de) * 2010-08-05 2012-02-09 Boehringer Ingelheim International Gmbh Säureadditionssalze des 2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-(methyl)amino]ethoxy]-n-methyl-n-[3-(4-methylpiperazin-1-yl)cyclohexyl]acetamids und ihre verwendung als bradykinin-b1 rezeptor antagonisten
WO2012022796A2 (de) 2010-08-20 2012-02-23 Boehringer Ingelheim International Gmbh Neue kombinationen
AR082890A1 (es) 2010-09-03 2013-01-16 Gruenenthal Gmbh Derivados sustituidos de tetrahidropirrolopirazina

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
EP1249233B9 (en) 1999-11-26 2009-08-05 Shionogi & Co., Ltd. Npyy5 antagonists
FR2819254B1 (fr) * 2001-01-08 2003-04-18 Fournier Lab Sa Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
FR2840897B1 (fr) * 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
EP1572678A4 (en) 2002-12-19 2008-05-07 Elan Pharm Inc SUBSTITUTED N-PHENYL SULPHONAMIDES ALSBRADYKININ ANTAGONISTS
CN1756551A (zh) * 2003-01-31 2006-04-05 普雷迪克医药品控股公司 新型芳基哌嗪基化合物
BRPI0408689B8 (pt) 2003-03-25 2021-05-25 Laboratoires Fournier S A derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
EP1799637A1 (en) * 2004-09-23 2007-06-27 Amgen, Inc Substituted sulfonamidopropionamides and methods of use
US20080090863A1 (en) 2004-09-30 2008-04-17 Taisho Pharmaceutical Co., Ltd. Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
DE102005013967A1 (de) 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2006071775A2 (en) 2004-12-29 2006-07-06 Elan Pharmaceuticals, Inc. Novel compounds useful for bradykinin b1 receptor antagonism
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
DE102007034620A1 (de) 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
EP2212281B1 (de) 2007-08-14 2011-03-23 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer wirkung
US8394805B2 (en) 2007-08-14 2013-03-12 Boehringer Ingelheim International Gmbh Compounds
DE102007046887A1 (de) 2007-09-28 2009-04-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von (1R,5S)-Anhydroecgoninestersalzen

Also Published As

Publication number Publication date
JP5250627B2 (ja) 2013-07-31
TW200911744A (en) 2009-03-16
ECSP109978A (es) 2010-03-31
AU2008288431A1 (en) 2009-02-19
CN101821245A (zh) 2010-09-01
MA31613B1 (fr) 2010-08-02
UY31287A1 (es) 2009-04-30
TN2010000072A1 (en) 2011-09-26
CO6331335A2 (es) 2011-10-20
CA2696261A1 (en) 2009-02-19
JP2010535839A (ja) 2010-11-25
PE20090593A1 (es) 2009-06-03
ZA201008350B (en) 2011-08-31
EA201000296A1 (ru) 2010-08-30
KR20100055469A (ko) 2010-05-26
AU2009281472A1 (en) 2010-02-18
US20110098282A1 (en) 2011-04-28
CN101821245B (zh) 2012-10-10
WO2009021944A1 (de) 2009-02-19
NZ583815A (en) 2012-03-30
EP2188269B1 (de) 2014-05-07
BRPI0815181A2 (pt) 2015-03-31
AR068341A1 (es) 2009-11-11
EP2188269A1 (de) 2010-05-26
US8394805B2 (en) 2013-03-12

Similar Documents

Publication Publication Date Title
TN2010000072A1 (en) New compounds
MY146623A (en) Substituted prolinamides, manufacturing, and the use thereof as medicaments
SG169338A1 (en) Aryl sulfonamides with an analgesic action
MY153941A (en) Compounds as bradykinin b1 antagonists
TW200738692A (en) New substituted glycinamides, process for their manufacture and use thereof as medicaments
WO2009013299A3 (de) Neue bradykinin b1-antagonisten
TW200738693A (en) Substituted biaryls, process for their manufacture and use thereof as medicaments
MX2009010218A (es) Derivados de aza-piridopirimidinona.
WO2009065919A3 (de) Organische verbindungen
WO2009065920A3 (de) Verbindungen
TW200602033A (en) New carboxylic acid amides, the preparation thereof and their use as medicaments
JO2734B1 (en) Organic compounds
WO2006114401A3 (en) Novel cyclic amines
WO2009065922A3 (de) Organische verbindungen
MY148769A (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
DE602006019732D1 (de) Indolylmaleimidderivate
WO2009021868A3 (en) Novel piperazine amide derivatives
MX2010003849A (es) Antagonistas de cgrp.
WO2009034029A3 (de) 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
GB0411929D0 (en) Organic compounds
WO2008135525A3 (en) Substituted azetidines, manufacturing and use thereof as medicaments
GB0602951D0 (en) Organic Compounds
WO2007048841A3 (de) Neue indol-haltige beta-agonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
TW200740798A (en) Substituted amides, process for their manufacture and use thereof as medicaments
MX2009008221A (es) Antagonista de receptor de cromeno s1p1.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration